Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Kai Wucherpfennig, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Kai Wucherpfennig and Stephanie Dougan.
Connection Strength

1.309
  1. cIAP1/2 antagonism eliminates MHC class I-negative tumors through T cell-dependent reprogramming of mononuclear phagocytes. Sci Transl Med. 2021 05 19; 13(594).
    View in: PubMed
    Score: 0.245
  2. Inhibition of CDK4/6 promotes CD8 T-cell memory formation. Cancer Discov. 2021 May 03.
    View in: PubMed
    Score: 0.244
  3. Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell. 2021 03 18; 184(6):1575-1588.
    View in: PubMed
    Score: 0.241
  4. Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. Cell. 2020 08 06; 182(3):655-671.e22.
    View in: PubMed
    Score: 0.230
  5. Rapid CLIP dissociation from MHC II promotes an unusual antigen presentation pathway in autoimmunity. J Exp Med. 2018 10 01; 215(10):2617-2635.
    View in: PubMed
    Score: 0.203
  6. In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature. 2014 Feb 06; 506(7486):52-7.
    View in: PubMed
    Score: 0.147
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.